RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Gfp - how confident can Cortex be that the two backup compounds won't show the same cellular modification issues that CX-717 has?

If I heard correctly, Dr. Stoll said the backup compounds have not show the same problem, but isn't it way too early to say that until they go through the same level of tox studies that CX-717 has?

Or does Cortex now know what to look for in early tox data that is a indication of the cellular problem and can thus extrapolate that the backup compounds won't show that problem?... Aiming4.